Takeda: all 1,753 studies

Page 18 of 18. Open to participants first (93), then studies with results posted, then the rest; newest registration first within each.

• Open Label Extension Study of PREOSCompletedNCT00172133Phase 3
• Open Label ExtensionCompletedNCT00172120Phase 3
• A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal OsteoporosisCompletedNCT00172107Phase 2
• Safety and Efficacy of NPS 1776 in the Acute Treatment of Migraine HeadachesCompletedNCT00172094Phase 2
• TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal OsteoporosisCompletedNCT00172081Phase 3
• Efficacy of Pantoprazole in Patients Older Than 18 Years Who Have Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/M3-339)CompletedNCT00163306Phase 3
• Pharmacokinetics, Efficacy and Safety Study of IMMUNATE SD (Human Plasma-Derived Coagulation Factor VIII Concentrate) in Hemophilia A PatientsCompletedNCT00162019Phase 3
• Efficacy and Safety Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Adult Subjects With Chronic Idiopathic Thrombocytopenic PurpuraCompletedNCT00162006Phase 2
• Safety, Pharmacokinetic and Efficacy Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Patients With Primary Immunodeficiency (Hypo- or Agammaglobulinemia)CompletedNCT00161993Phase 2
• Retrospective Study to Capture Dosing and Treatment Outcome Data in Participants With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use INDCompletedNCT00161720
• Safety Study of an Aerosolized, Recombinant Alpha 1-Antitrypsin in Subjects With Alpha 1-Antitrypsin DeficiencyCompletedNCT00161707Phase 1/2
• Efficacy and Safety of Fosrenol in Treating Elevated Serum Phosphate Levels in Adults With End Stage Renal DiseaseCompletedNCT00160121Phase 4
• Efficacy and Safety Study of Protein C Concentrate in Subjects With Severe Congenital Protein C DeficiencyCompletedNCT00157118Phase 2/3
• Safety and Efficacy Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients Undergoing SurgeryCompletedNCT00157105Phase 2/3
• Study of the Effect of Aerosolized, Recombinant Alpha 1-Antitrypsin on Epithelial Lining Fluid Analytes in Subjects With Alpha 1-Antitrypsin DeficiencyCompletedNCT00157092Phase 1/2
• Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency DisordersCompletedNCT00157079Phase 3
• Study of Pharmacokinetics, Efficacy and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients - A Continuation of Clinical Study 069901CompletedNCT00157053Phase 2/3
• Study of Pharmacokinetics, Efficacy, and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients With Hemophilia ACompletedNCT00157040Phase 2/3
• Safety of SPD465 in Treating Adults With ADHD.CompletedNCT00152035Phase 3
• Efficacy and Safety of SPD465 in Adults With Moderately Symptomatic ADHD.CompletedNCT00152022Phase 3
• Safety and Tolerability of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis.CompletedNCT00151944Phase 3
• Efficacy and Tolerability of Treatment With Lanthanum Carbonate in Patients With End Stage Renal Disease Receiving DialysisCompletedNCT00151931Phase 3
• Efficacy and Safety of Lanthanum Carbonate and Sevelamer Hydrochloride in Patients Receiving Haemodialysis for End Stage Renal DiseaseCompletedNCT00151918Phase 3
• Efficacy and Safety of SPD465 in Adults With ADHDCompletedNCT00150579Phase 3
• Efficacy and Safety of Lanthanum in Controlling Serum Phosphate Levels in Subjects With End Stage Renal Disease Who Require Treatment for High Levels of Phosphate in Their BloodCompletedNCT00150566Phase 3
• A Long Term Study of Lanthanum Carbonate in Patients Requiring Dialysis Who Have Ived Lanthanum Carbonate in Previous Studies Defined by the Protocol.CompletedNCT00150540Phase 3
• Efficacy of Lapaquistat Acetate and Atorvastatin on Blood Cholesterol Levels in Subjects With Primary HypercholesterolemiaCompletedNCT00143676Phase 3
• Effect of Lapaquistat Acetate on Blood Cholesterol Levels in Subjects With Elevated CholesterolCompletedNCT00143663Phase 3
• Efficacy & Safety of Resatorvid in Adults With Severe SepsisCompletedNCT00143611Phase 3
• Ketoconazole Administration: How it is Affected by the Body and Broken Down and How it Acts on the Body When Used With VelcadeCompletedNCT00129207Phase 1
• Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.TerminatedNCT00117884Phase 2
• VELCADE in Previously Treated Patients With Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma With BAC FeaturesTerminatedNCT00117351Phase 2
• VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previously Untreated Multiple MyelomaCompletedNCT00111319Phase 3
• VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell LymphomaCompletedNCT00085696Phase 2
• Repeat-Dose Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients With Relapsed Multiple MyelomaCompletedNCT00080405Phase 1
• Venticute in Patients With Pneumonia or Aspiration of Gastric Contents and Intubation/Ventilation/Oxygenation Impairment (BY2001/M1-007)CompletedNCT00074906Phase 3
• Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's DiseaseCompletedNCT00072839Phase 2
• MLN2704 in Subjects With Metastatic Androgen-Independent Prostate CancerCompletedNCT00070837Phase 1/2
• Phase I Dose Escalation Study of VELCADE Plus Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer or Other Solid TumorsTerminatedNCT00064636Phase 1
• Phase I/II Dose Escalation Study of VELCADE® and Docetaxel in Patients With Advanced Androgen-Independent Prostate CancerCompletedNCT00064610Phase 1/2
• Safety and Tolerance Study of Oral Doses of CT53518 to Treat Patients With Acute Myelogenous Leukemia (AML)CompletedNCT00064584Phase 1
• A Study to Assess Two Different Strategies of Combining Dexamethasone and VELCADENo longer availableNCT00063791
• A Study of PS-341 Given to Patients With Multiple Myeloma Who Experienced Progressive Disease After Receiving Dexamethasone in M34101-039CompletedNCT00063726Phase 3
• VELCADE in Subjects With Relapsed or Refractory Mantle Cell LymphomaCompletedNCT00063713Phase 2
• A Trial of MLN2704 in Subjects With Metastatic Androgen Independent Prostate CancerCompletedNCT00052000Phase 1
• Phase 2b Study of VELCADE Alone and VELCADE Plus Irinotecan in Patients With Relapsed or Refractory Colorectal CarcinomaCompletedNCT00051987Phase 2
• Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung CancerCompletedNCT00051974Phase 2
• Safety and Efficacy Study of Once and Twice Daily Doses of MCC-135 in Subjects With Congestive Heart Failure.CompletedNCT00050076Phase 2
• PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00048230Phase 3
• A Phase IV Study in Subjects With Neurogenic Orthostatic HypotensionTerminatedNCT00046163Phase 4
• Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2CompletedNCT00034281Phase 1
• Troxacitabine in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00012259Phase 2
• Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell TransplantationTerminatedNCT00003056Phase 3

← Takeda overview and focus areas